Silk Road Medical to be acquired by Boston Scientific for $27.50 per share

Silk Road Medical (SILK) entered into a definitive agreement to be acquired by Boston Scientific Corporation (BSX) for $27.50 in cash per share, representing an equity value of approximately $1.26 billion. The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical’s common stock over the past 60 days. The board of directors of Silk Road has unanimously approved the transaction and recommend that Silk Road stockholders adopt the merger agreement. The transaction is expected to close in the second half of 2024, subject to the satisfaction of customary closing conditions, including approval by Silk Road’s stockholders and applicable regulatory approvals. Upon the completion of the transaction, Silk Road will become a wholly-owned subsidiary of Boston Scientific.